This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hasegawa, K. Articles by Peng, K.-W. Search for Related Content PubMed PubMed Citation Articles by Hasegawa, K. Articles by Peng, K.-W.

Dual Therapy of Ovarian Cancer Using Measles Viruses Expressing Carcinoembryonic Antigen and Sodium Iodide Symporter

Authors' Affiliations: ¹ Molecular Medicine Program, ² Nuclear Medicine, and ³ Viral Vector Production Laboratory, Mayo Clinic College of Medicine, Rochester, Minnesota

Requests for reprints: Kah-Whye Peng, Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-8357; Fax: 507-284-8388; E-mail: peng.kah{at}mayo.edu.

Purpose: MV-CEA is an oncolytic measles virus currently being tested in patients with ovarian cancer and whose propagation can be monitored by measuring blood carcinoembryonic antigen (CEA) levels. MV-NIS is an oncolytic measles virus coding for the thyroidal sodium iodide symporter (NIS) whose propagation can be mapped by serial radioiodine imaging. Expression of both CEA and NIS genes from a single virus would combine sensitive, quantitative expression monitoring (CEA) with radioisotopic expression mapping (NIS). Because of the unfavorable replication kinetics of measles viruses expressing both CEA and NIS, we explored the feasibility of combining MV-CEA with MV-NIS for comprehensive virotherapy monitoring in ovarian cancer.

Experimental Design and Results: Mice implanted with i.p. SKOV3ip.1 ovarian cancer xenografts received MV-CEA alone, MV-NIS alone, or a combination of MV-CEA plus MV-NIS. Viral gene expression was monitored by measuring blood CEA levels, and the location of virus-infected cells was monitored by gamma camera imaging. Surprisingly, mice receiving the combination of MV-CEA plus MV-NIS showed greatly superior responses to therapy, but this was associated with 10-fold lower plasma levels of CEA compared with mice treated with MV-CEA alone. In vitro studies showed superior replication kinetics of MV-NIS relative to MV-CEA. The gamma camera scans were considerably less sensitive than the plasma CEA marker for monitoring virus infection.

Conclusions: Dual therapy with MV-CEA and MV-NIS is superior to treatment with either virus alone, and it allows noninvasive monitoring of virotherapy via soluble marker peptide and gamma camera imaging. This has important implications for the clinical development of oncolytic measles viruses.

This article has been cited by other articles:

				S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene Am. J. Roentgenol., January 1, 2009; 192(1): 279 - 287. [Abstract] [Full Text] [PDF]

				K. Hasegawa, C. Hu, T. Nakamura, J. D. Marks, S. J. Russell, and K.-W. Peng Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins J. Virol., December 1, 2007; 81(23): 13149 - 13157. [Abstract] [Full Text] [PDF]

				J. N. Sarkaria, L. Yang, P. T. Grogan, G. J. Kitange, B. L. Carlson, M. A. Schroeder, E. Galanis, C. Giannini, W. Wu, E. B. Dinca, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel Mol. Cancer Ther., March 1, 2007; 6(3): 1167 - 1174. [Abstract] [Full Text] [PDF]

				K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF]